Chester County News and Community Website
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) reported that up to 93% of patients taking its liver disease drug Rezdiffra experienced improved or stable liver stiffness measurements after approximately …
Madrigal Reports Liver Improvements in Rezdiffra Studies Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) reported its first profitable quarter as sales of its liver disease treatment Rezdiffra rose 50% to $431.3 million in the third quarter …
Madrigal Turns Profitable as Rezdiffra Sales Surge 50% Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) will present new clinical and real-world research on its liver disease treatment Rezdiffra at a medical conference in Denver beginning November 5, …
Madrigal Expands Rezdiffra Evidence With 12,000-Patient Study Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) will report third-quarter 2026 financial results on November 3, providing investors with an update on the commercial performance of Rezdiffra, its approved …
Madrigal Sets November 3 Earnings Report as MASH Drug Expands Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) granted 9,642 restricted stock units to 26 newly hired non-executive employees in October, using equity compensation to support recruitment as the biotechnology …
Madrigal Grants Equity Awards to 26 New Employees Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) reported that its liver disease drug Rezdiffra improved measures of liver damage across patients carrying common genetic risk variants for metabolic dysfunction-associated …
Madrigal Study Finds Rezdiffra Benefits Across Genetic Risks Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) granted stock options and restricted stock units to 27 newly hired non-executive employees in September, using equity incentives to support hiring as …
Madrigal Grants Equity Awards to 27 New Employees Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) will present at the Cantor Global Healthcare Conference on Sept. 10, putting the commercial and clinical strategy around its MASH treatment Rezdiffra …
Madrigal to Put MASH Drug Strategy Before Investors at Cantor Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) recently granted 4,676 restricted stock units to 13 newly hired non-executive employees on Aug. 15 as employment inducements, extending equity compensation to …
Madrigal Grants Stock Awards to 13 New Employees Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) appointed Johnson & Johnson research executive John C. Reed, M.D., Ph.D., to its board of directors as the biopharmaceutical company builds on …
Madrigal Adds J&J R&D Chief to Board as MASH Push Expands Read More